Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment
Clinical trial NCT06762925 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06762925
- Sponsor
- Xijing Hospital
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-01-30
- Primary completion
- 2026-06-01
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.